Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like M*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000052	Mallinckrodt Hospital Products Inc.	03/31/2020	43825010201	OFIRMEV INJECTION 1000MG/100ML (10mg/ml) (24 vials/case)	01/02/2020	93.87	1136.87	03/11/2032	Single Source Drug	None	1	None	1	Mallinckrodt has voluntarily made a public pledge on responsible drug pricing and innovation which is our social contract to those we serve and which can be found at https://www.mallinckrodt.com/corporate-responsibility/pledge-on-drug-pricing--innovation/. Our commitment is to price our innovative products responsibly while providing broad patient access. In so doing, we continue to invest in innovation that brings value to patients, providers, and the U.S. healthcare system through research and development, quality manufacturing, as well as through patient education and disease awareness. The current price increase for Ofirmev is not necessitated by a change or improvement to the drug but by the larger principles set forth in our pledge.	None	03/19/2014	Cadence Pharmaceuticals, Inc.	1400000000	None	Acquisition Price field reflects the total price paid for all of Cadence inclusive of Ofirmev	354.00	None	2011	258.00	None	None
Rx0000072	Mayne Pharma Inc	03/31/2020	51862006410	DIAZEPAM 10MG TABLETS 1000	01/03/2020	90.80	181.60	None	Non-innovator Multiple Source Drug	10676	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	None	Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	36.32	36.32	2005	36.32	None	None
Rx0000072	Mayne Pharma Inc	03/31/2020	51862094310	DIAZEPAM 10MG TABLETS 1000 (NEW MAYNE NDC)	01/03/2020	90.80	181.60	None	Non-innovator Multiple Source Drug	10676	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	None	Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	36.32	36.32	2005	36.32	None	NEW PRODUCT NDC
Rx0000072	Mayne Pharma Inc	03/31/2020	51862006405	DIAZEPAM 10MG TABLETS 500	01/03/2020	46.33	92.66	None	Non-innovator Multiple Source Drug	9676	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	None	Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	18.53	18.53	2005	18.53	None	None
Rx0000072	Mayne Pharma Inc	03/31/2020	51862094305	DIAZEPAM 10MG TABLETS 500 (NEW MAYNE NDC)	01/03/2020	46.33	92.66	None	Non-innovator Multiple Source Drug	455	None	CHANGING MARKET DYNAMICS	None	NONE	None	None	None	None	None	None	None	None	None	None	None	NEW PRODUCT NDC
Rx0000072	Mayne Pharma Inc	03/31/2020	51862006205	DIAZEPAM 2MG TABLETS 500	01/03/2020	34.20	68.40	None	Non-innovator Multiple Source Drug	9040	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	None	Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	13.68	13.68	2005	13.68	None	None
Rx0000072	Mayne Pharma Inc	03/31/2020	51862006310	DIAZEPAM 5MG TABLETS 1000	01/03/2020	69.85	139.70	None	Non-innovator Multiple Source Drug	4444	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	None	Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	27.94	27.94	2001	42.95	None	None
Rx0000072	Mayne Pharma Inc	03/31/2020	51862094210	DIAZEPAM 5MG TABLETS 1000 (NEW MAYNE NDC)	01/03/2020	69.85	139.70	None	Non-innovator Multiple Source Drug	1	None	CHANGING MARKET DYNAMICS	None	NONE	None	None	None	None	None	None	None	None	None	None	None	NEW PRODUCT NDC, NO SALES AS OF 04-30-2020; USED 1 AS A PLACEHOLDER TO SUBMIT INCREASE
Rx0000072	Mayne Pharma Inc	03/31/2020	51862006305	DIAZEPAM 5MG TABLETS 500	01/03/2020	35.65	71.30	None	Non-innovator Multiple Source Drug	35620	None	CHANGING MARKET DYNAMICS	None	NONE	None	08/03/2016	ALLERGAN	None	None	Diazepam was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million.	14.26	14.26	2005	14.26	None	None
Rx0000072	Mayne Pharma Inc	03/31/2020	51862094205	DIAZEPAM 5MG TABLETS 500 (NEW MAYNE NDC)	01/03/2020	35.65	71.30	None	Non-innovator Multiple Source Drug	11479	None	CHANGING MARKET DYNAMICS	None	NONE	None	None	None	None	None	None	None	None	None	None	None	NEW PRODUCT NDC
Rx0000072	Mayne Pharma Inc	03/31/2020	51862029510	Fabior External Foam 0.1 % 100g Can	01/13/2020	80.65	1155.94	02/24/2030	Single Source Drug	11455	None	None	1	None	None	08/17/2016	GlaxoSmithKline LLC	None	1	None	830.32	722.02	2014	607.76	None	Product NDC at WAC Introduction in 2014 was 00145-0020-02. Product WAC Introduction for current 51862-0295-10 NDC was $830.32 on 03/17/2017. Unit Sales reported for calendar year 2019.
Rx0000072	Mayne Pharma Inc	03/31/2020	51862029550	Fabior External Foam 0.1 % 50g Can	01/13/2020	40.32	577.96	02/24/2030	Single Source Drug	96108	None	None	1	None	None	08/17/2016	GlaxoSmithKline LLC	None	1	None	415.16	361.01	2014	303.88	None	Product NDC at WAC Introduction in 2014 was 00145-0020-03. Product WAC Introduction for current 51862-0295-50 NDC was $415.16 on 03/03/2017. Unit Sales reported for calendar year 2019.
Rx0000072	Mayne Pharma Inc	03/31/2020	51862015904	Hydrocortisone Butyrate External Lotion 0.1 % 118ML PER BOTTLE	01/28/2020	439.45	894.10	None	Non-innovator Multiple Source Drug	279	None	Initial launch price listed on 8/23/2019 was for a different pack size. Price change is to update to correct pack size.	None	None	None	None	None	None	None	None	None	None	None	None	None	Product was not acquired; this is a licensing deal with Teligent.
Rx0000072	Mayne Pharma Inc	03/31/2020	51862037612	Sorilux External Foam 0.005 % 120g Can	01/13/2020	110.51	1583.97	05/07/2028	Single Source Drug	4615	None	None	1	None	None	08/17/2016	GlaxoSmithKline LLC	None	1	None	1240.18	1078.42	2012	650.00	None	Product NDC at WAC Introduction in 2012 was 00145-2130-07. Product WAC Introduction for current 51862-0376-12 NDC was $1240.18 on 05/11/2017. Unit Sales reported for calendar year 2019.
Rx0000072	Mayne Pharma Inc	03/31/2020	51862037660	Sorilux External Foam 0.005 % 60g Can	01/13/2020	57.80	828.52	05/07/2028	Single Source Drug	29204	None	None	1	None	None	08/17/2016	GlaxoSmithKline LLC	None	1	None	648.70	564.09	2012	340.00	None	Product NDC at WAC Introduction in 2012 was 00145-2130-06. Product WAC Introduction for current 51862-0376-60 NDC was $648.7 on 05/11/2017. Unit Sales reported for calendar year 2019.
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538050106	Ciclodan Kit, 8%, TOPSOL, 34.60 ML	07/31/2020	10.85	444.88	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538050006	Ciclodan Topical Solution, 8%, TOPSOL, 6.60 ML	07/31/2020	10.85	444.88	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538017360	Clindacin ETZ Kit, 1%, TOPCMB, 1 EA	07/31/2020	15.20	623.14	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538017260	Clindacin ETZ, 1%, SGPDSW, 60 EA	07/31/2020	15.20	623.14	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538017069	Clindacin P, 1%, SGPDSW, 69 EA	07/31/2020	15.20	623.14	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538017169	Clindacin Pac, 1%, TOPCMB, 1 EA	07/31/2020	15.20	623.14	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538095104	Clodan Kit, 0.05%, TOPCMB, 1 EA	07/31/2020	15.22	623.90	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538095004	Clodan Shampoo, 0.05%, TOPSHMPO, 118 ML	07/31/2020	15.22	623.90	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538051112	Genadur Kit, 2500MCG, COMB, 1 EA	07/31/2020	12.48	511.67	None	Single Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538051012	Genadur, TOPLIQ, 12 ML	07/31/2020	12.48	511.67	None	Single Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538094160	Neo-Synalar Cream Kit, 0.5-0.025%, EXTCRM, 315 GM	07/31/2020	20.11	824.25	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538094060	Neo-Synalar Cream, 0.5-0.025%, EXTCRM, 60 GM	07/31/2020	20.11	824.25	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538017645	Neuac Gel, 1.2(1)%-5%, TOPGEL, 45 GM	07/31/2020	14.79	606.52	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538017745	Neuac Kit, 1.2(1)%-5%, TOPCMB, 130 GM	07/31/2020	14.79	606.52	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538044060	Nicadan, 800-10-100, TAB, 60 EA	07/31/2020	11.29	463.17	None	Single Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538018145	Rosadan Cream Kit, 0.75%, RCTCMB, 1 EA	07/31/2020	11.93	489.26	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538018045	Rosadan Cream, 0.75%, EXTCRM, 45 GM	07/31/2020	11.93	489.26	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538018345	Rosadan Gel Kit, 0.75%, TOPCMB, 1 EA	07/31/2020	11.93	489.27	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538018245	Rosadan Gel, 0.75%, TOPGEL, 45 GM	07/31/2020	11.93	489.27	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538019116	Sumadan Kit, 9%-4.5%, TOPCMB, 1 EA	07/31/2020	19.98	818.87	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538019016	Sumadan Wash, 9%-4.5%, TOPCLNSR, 454 GM	07/31/2020	19.98	818.87	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538019216	Sumadan XLT, 9%-4.5%, TOPCMB, 539 GM	07/31/2020	19.98	818.87	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538010060	Sumaxin Cleansing Pad, 10%-4%, SGPDSW, 60 EA	07/31/2020	20.48	839.49	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538010160	Sumaxin CP Kit, 10%-4%, TOPCMB, 1 EA	07/31/2020	20.48	839.49	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538016016	Sumaxin TS, 8%-4%, TOPSUSP, 473 ML	07/31/2020	15.73	644.97	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538013016	Sumaxin Wash, 9%-4%, TOPCLNSR, 454 GM	07/31/2020	17.84	731.32	None	Non-innovator Multiple Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538090112	Synalar Cream Kit, 0.025%, EXTCRM, 375 GM	07/31/2020	14.01	574.46	None	Single Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538090012	Synalar Cream, 0.025%, EXTCRM, 120 GM	07/31/2020	14.01	574.46	None	Single Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538091112	Synalar Ointment Kit, 0.025%, TOPCMB, 375 GM	07/31/2020	14.01	574.46	None	Single Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000202	Medimetriks Pharmaceuticals, Inc	09/30/2020	43538091012	Synalar Ointment, 0.025%, EXTONT, 120 GM	07/31/2020	14.01	574.46	None	Single Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000138	Merck & Co., Inc.	03/31/2020	00006003330	BELSOMRA 10 mg Tablets 30	01/03/2020	17.40	365.70	05/29/2033	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	03/31/2020	00006032530	BELSOMRA 15 mg Tablets 30	01/03/2020	17.40	365.70	05/29/2033	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	03/31/2020	00006033530	BELSOMRA 20 mg Tablets 30	01/03/2020	17.40	365.70	05/29/2033	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	03/31/2020	00006000530	BELSOMRA 5 mg Tablets 30	01/03/2020	17.40	365.70	05/29/2033	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	03/31/2020	67919002010	ENTEREG 12 mg Capsules 30	01/03/2020	242.70	5195.40	02/12/2030	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	03/31/2020	00052031301	FOLLISTIM AQ 300 unit/0.36 mL CARTRIDGE (ML) 0.42	01/03/2020	36.00	792.00	None	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00052031601	FOLLISTIM AQ 600 unit/0.72 mL deliverable (833 unit/mL) CARTRIDGE (ML) 0.78	01/03/2020	72.00	1584.00	None	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	03/31/2020	00052032601	FOLLISTIM AQ 900 unit/1.08 mL CARTRIDGE (ML) 1.17	01/03/2020	108.00	2376.00	None	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	12/31/2020	00006412102	GARDASIL 9 0.5 mL Syringes 10	11/12/2020	113.59	2385.40	12/10/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	12/31/2020	00006411903	GARDASIL 9 0.5 mL Vials 10	11/12/2020	113.59	2385.40	12/10/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	03/31/2020	00006047761	ISENTRESS 100 mg Chewable Tablets 60	01/03/2020	19.68	413.28	09/11/2029	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) the patent expiration date for this product includes 6 month pediatric exclusivity.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006047361	ISENTRESS 25 mg Chewable Tablets 60	01/03/2020	4.92	103.32	09/11/2029	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) the patent expiration date for this product includes 6 month pediatric exclusivity.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006022761	ISENTRESS 400 mg Tablets 60	01/03/2020	78.72	1653.12	09/11/2029	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) the patent expiration date for this product includes 6 month pediatric exclusivity.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006308001	ISENTRESS HD 600 mg Tablets 60	01/03/2020	78.72	1653.12	04/21/2031	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years); (3) the patent expiration date for this product includes 6 month pediatric exclusivity.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006057782	JANUMET 50 mg-1000 mg Tablets 1000	01/03/2020	370.00	7890.00	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006057762	JANUMET 50 mg-1000 mg Tablets 180	01/03/2020	66.60	1420.20	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006057761	JANUMET 50 mg-1000 mg Tablets 60	01/03/2020	22.20	473.40	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006057582	JANUMET 50 mg-500 mg Tablets 1000	01/03/2020	370.00	7890.00	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006057562	JANUMET 50 mg-500 mg Tablets 180	01/03/2020	66.60	1420.20	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006057561	JANUMET 50 mg-500 mg Tablets 60	01/03/2020	22.20	473.40	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006008182	JANUMET XR 100 mg-1000 mg Tablets 1000	01/03/2020	740.00	15780.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006008131	JANUMET XR 100 mg-1000 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006008154	JANUMET XR 100 mg-1000 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006008082	JANUMET XR 50 mg-1000 mg Tablets 1000	01/03/2020	370.00	7890.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006008062	JANUMET XR 50 mg-1000 mg Tablets 180	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006008061	JANUMET XR 50 mg-1000 mg Tablets 60	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006007882	JANUMET XR 50 mg-500 mg Tablets 1000	01/03/2020	370.00	7890.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006007862	JANUMET XR 50 mg-500 mg Tablets 180	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2 )the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006007861	JANUMET XR 50 mg-500 mg Tablets 60	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006027728	JANUVIA 100 mg Tablets 100	01/03/2020	74.00	1578.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006027782	JANUVIA 100 mg Tablets 1000	01/03/2020	740.00	15780.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006027731	JANUVIA 100 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006027754	JANUVIA 100 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006022128	JANUVIA 25 mg Tablets 100	01/03/2020	74.00	1578.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006022131	JANUVIA 25 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006022154	JANUVIA 25 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006011228	JANUVIA 50 mg Tablets 100	01/03/2020	74.00	1578.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006011231	JANUVIA 50 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	03/31/2020	00006011254	JANUVIA 50 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
Rx0000138	Merck & Co., Inc.	12/31/2020	00006468100	M-M-R II 0.5 mL Vials 10	11/12/2020	38.21	802.49	None	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	12/31/2020	00006483703	PNEUMOVAX 23 0.5 mL Syringes 10	11/12/2020	52.60	1104.54	None	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	12/31/2020	00006494300	PNEUMOVAX 23 0.5 mL Vials 10	11/12/2020	52.60	1104.54	None	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	12/31/2020	00006417100	PROQUAD 0.5 mL Vials 10	11/12/2020	110.97	2330.34	None	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	12/31/2020	00006482700	VARIVAX 0.5 mL Vials 10	11/12/2020	67.49	1417.24	None	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck & Co., Inc.	03/31/2020	67919003001	ZERBAXA 1.5 gram Vial 10	01/03/2020	112.80	1252.20	08/14/2035	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
Rx0000051	MILLICENT U.S., INC.	03/31/2020	72495020105	FEMRING 0.05MG/DAY (ESTRADIOL ACETATE VAGINAL RING) for 3 months usage, package size 1	01/01/2020	46.12	531.49	None	Single Source Drug	None	1	None	1	None	1	05/18/2018	Allergan	None	1	None	443.67	None	2003	76.50	None	None
Rx0000051	MILLICENT U.S., INC.	03/31/2020	72495020210	FEMRING 0.10MG/DAY (ESTRADIOL ACETATE VAGINAL RING) for 3 months usage, package size 1	01/01/2020	49.14	566.37	None	Single Source Drug	None	1	None	1	None	1	05/18/2018	Allergan	None	1	None	472.79	None	2003	81.50	None	None
Rx0000318	Mission Pharmacal Company	12/31/2020	00178074001	URIBEL, methenamine 118mg, sodium phosphate monobasic 40.8mg, phenyl salicylate 10mg, methylene blue 10mg, and hyoscyamine sulfate capsule 0.12mg, 100 capsules	10/01/2020	26.33	355.44	None	Non-innovator Multiple Source Drug	None	1	Product was acquired from another labeler	None	No formulation changes were made, just Labeler change	None	01/01/2019	Star Pharmaceuticals, LLC	None	1	Additional Information is needed, no enough or clear information is provided in the sample form	313.44	290.22	2010	170.00	None	None
Rx0000296	MOLECULAR BIOLOGICALS INC	09/30/2020	71474030310	KERAMATRIX WOUND DRESSING 10CMX10CM 10'S	07/01/2020	22485.00	29980.00	None	Single Source Drug	100	None	COMPETITIVE MARKET ANALYSIS	None	No change	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000296	MOLECULAR BIOLOGICALS INC	09/30/2020	71474030350	KERAMATRIX WOUND DRESSING 10CMX10CM 5'S	07/01/2020	11242.50	14990.00	None	Single Source Drug	100	None	COMPETITIVE MARKET ANALYSIS	None	No change	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000296	MOLECULAR BIOLOGICALS INC	09/30/2020	71474030301	KERAMATRIX WOUND DRESSING 10CMX10CM SINGLE	07/01/2020	2248.50	2998.00	None	Single Source Drug	100	None	COMPETITIVE MARKET ANALYSIS	None	No change	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000296	MOLECULAR BIOLOGICALS INC	09/30/2020	71474030351	KERAMATRIX WOUND DRESSING 5CMX5CM 10'S	07/01/2020	3970.10	7495.00	None	Single Source Drug	100	None	COMPETITIVE MARKET ANALYSIS	None	No change	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000296	MOLECULAR BIOLOGICALS INC	09/30/2020	71474030355	KERAMATRIX WOUND DRESSING 5CMX5CM 5'S	07/01/2020	1985.05	3747.50	None	Single Source Drug	100	None	COMPETITIVE MARKET ANALYSIS	None	No change	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000296	MOLECULAR BIOLOGICALS INC	09/30/2020	71474030305	KERAMATRIX WOUND DRESSING 5CMX5CM SINGLE	07/01/2020	397.01	749.50	None	Single Source Drug	100	None	COMPETITIVE MARKET ANALYSIS	None	No change	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000044	Mylan Institutional Inc	09/30/2020	67457022005	Isosulfan Blue 1% 50mg/5mL Liq 6s SUV	07/21/2020	288.68	6062.23	12/15/2028	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1)NDC 67457-0220-00 is an innerpack of the NDC 67457-0220-05. As defined in the CA Code of Regulations Title 22, Divsion 7, Chapters 9.5 ("Regulations"), “Wholesale Acquisition Cost (“WAC”)” means a manufacturer’s published list price for a prescription drug product with a unique NDC. Because the innerpack is not commercially available for sale by Mylan, Mylan does not submit pricing to the pricing compendium and has no control on what the pricing compendium posts for these innerpack NDCs. Therefore, since there is no applicable WAC as defined in the Regulations for the innerpack NDC, Mylan is reporting only for the commercially available NDC 67457-0220-05. (2)FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. (3) Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V.
Rx0000044	Mylan Institutional Inc	09/30/2020	67457025905	Isosulfan Blue N+ 1% 50mg/5mL Liq 6s SUV	07/21/2020	288.68	6062.23	12/15/2028	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. (2) Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V.
Rx0000044	Mylan Institutional Inc	09/30/2020	67457058605	Isosulfan Blue PRX 1% 50mg/5mL Liq 6s SUV	07/21/2020	288.68	6062.23	12/15/2028	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) NDC 67457-0586-00 is an innerpack of the NDC 67457-0586-05. As defined in the CA Code of Regulations Title 22, Divsion 7, Chapters 9.5 ("Regulations"), “Wholesale Acquisition Cost (“WAC”)” means a manufacturer’s published list price for a prescription drug product with a unique NDC. Because the innerpack is not commercially available for sale by Mylan, Mylan does not submit pricing to the pricing compendium and has no control on what the pricing compendium posts for these innerpack NDCs. Therefore, since there is no applicable WAC as defined in the Regulations for the innerpack NDC, Mylan is reporting only for the commercially available NDC 67457-0586-05. (2) FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. (3) Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan N.V.